Orexin Receptor Antagonist [EPC] — Patent Landscape

Aggregated US Orange Book patent estate across every drug in the orexin receptor antagonist [epc] class. 8 active patents protecting 1 drugs. First major cliff: 2031. Daily refresh.

1
Drugs in class
8
Active US patents
60/100
Avg vulnerability
—
Annual revenue covered

Originators

Eisai 8 patents

Cliff calendar — next 15 years

2
31
6
35

Drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Dayvigo
LEMBOREXANT
 Eisai 8 60 — 2031-09-20

Most attackable patents

Patent Drug Type Vuln Expiry
8268848 Dayvigo method of use 68 2031-09-20
8268848 Dayvigo method of use 68 2031-09-20
10188652 Dayvigo method of use 62 2035-10-21
10188652 Dayvigo method of use 62 2035-10-21
11026944 Dayvigo formulation 55 2035-10-21
10702529 Dayvigo formulation 55 2035-10-21
10702529 Dayvigo formulation 55 2035-10-21
11026944 Dayvigo formulation 55 2035-10-21

Strongest defences

Patent Drug Type Vuln Expiry
11026944 Dayvigo formulation 55 2035-10-21
10702529 Dayvigo formulation 55 2035-10-21
10702529 Dayvigo formulation 55 2035-10-21
11026944 Dayvigo formulation 55 2035-10-21
10188652 Dayvigo method of use 62 2035-10-21
10188652 Dayvigo method of use 62 2035-10-21
8268848 Dayvigo method of use 68 2031-09-20
8268848 Dayvigo method of use 68 2031-09-20

Related